Skip to main content
Explore URMC

menu

Lymphoma: A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Research Question:
Will the antibody (a type of human protein) nivolumab help the body's immune system to work against tumor cells?

Basic Study Information

Purpose:
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558) in combination with brentuximab vedotin. Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow the body’s immune system to work against tumor cells. Brentuximab vedotin is an antibody-drug conjugate (a type of human protein linked to a study drug). The antibody part of the drug binds to CD30 which often occurs on diseased cells but rarely on normal tissues.

Location: cancer center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02581631?term=CA209-436&rank=1
Study Reference #: ILYM-15097

Lead Researcher (Principal Investigator)

Lead Researcher: Paul Barr

Study Contact Information

Study Coordinator: Yelena Lerman
Phone: (585) 276-8333
Email: Yelena_lerman@urms.rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Lymphoma, Non-Hodgkin

Return to Search